The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer.

PURPOSES We aimed to investigate the concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid (CSF) and to explore their clinical value in the meningeal carcinomatosis (MC) of lung cancer. So that, sensitive and specificity of CSF examination can be improved in the initial diagnosis of MC. METHOD A total of 35 lung cancer patients and 35 patients with benign brain tumor in the same period enrolled in this study. The concentrations of tumor markers CEA, CYFRA 21-1 and NSE in CSF and peripheral blood were examined. RESULT The concentrations of three tumor markers of CYFRA 21-1, NSE and CEA in blood serum and CSF were obviously higher than that of benign disease group. In MC patients, the concentrations of three tumor markers of CYFRA 21-1, NSE and CEA in blood serum were significant lower than that in CSF. The maximum of Youden's index was identified as the cutoff value of indicator of MC in three tumor markers in CSF which were CEA > 4.7 μg/L, NSE > 14.6 μg/L and CYFRA21-1 > 5.5 μg/L respectively. Based on the cutoff values, the CEA had the highest sensitivity while the CYFRA21-1 had the highest specificitiy. Three tumor markers in the CSF had higher positive rate than those in blood serum. We combined the levels of CEA, NSE and CYFRA21-1 in CSF to diagnosis of MC. Positive of CEA or CYFRA21-1 had the greatest sensitivity of 100% while the specificity of 91.4%; the positive of both CEA and CYFRA21-1 had the highest specificity of 100% while the sensitivity of 74.3%. Both positive predictive value and negative predictive value were 100% when combination positive were confirmed when the all three markers were positive. CONCLUSION The combination of CEA and CYFRA21-1 can be recommended in early screening of meningeal carcinoma. Especially, for the patient who was difficult to be diagnosed by CSF histology and MRI, it will be a useful auxiliary marker in diagnosis of MC. The combination of CEA, NSE and CYFRA21-1 can be an effective clinically confirmation and exclusively diagnose indictor of MC.

[1]  J. Sørensen,et al.  Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. , 2012, Lung cancer.

[2]  Ludmilla T. D. Chinen,et al.  Meningeal carcinomatosis in solid tumors. , 2011, Arquivos de neuro-psiquiatria.

[3]  Bo Wang,et al.  Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: A single center analysis , 2011, Cancer biology & therapy.

[4]  M. Arya,et al.  Non-small cell lung carcinoma presenting as carcinomatous meningitis , 2010, Lung India : official organ of Indian Chest Society.

[5]  J. Werner,et al.  Cyfra 21-1 as a Tumor Marker for Follow-up of Patients with Squamous Cell Carcinoma of the Oropharnyx , 2010 .

[6]  R. Lamerz,et al.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. , 2010, Clinical chemistry.

[7]  T. Noguchi,et al.  [Carcinomatous meningitis in gastric cancer under chemotherapy-two cases]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[8]  L. Rogers.  Neurologic Complications of Cancer, 2nd ed. , 2009 .

[9]  K. Hoang-Xuan,et al.  Leptomeningeal metastases from solid malignancy: a review , 2005, Journal of Neuro-Oncology.

[10]  P. Wen,et al.  Neurologic Complications of Cancer , 2003 .

[11]  T. Merchant,et al.  Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Ropper,et al.  Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barre syndrome , 1996, Neurology.

[13]  A. Howell,et al.  Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant , 1994, Cancer.

[14]  G. Lai,et al.  Meningeal carcinomatosis from solid tumors: clinical analysis of 42 cases. , 1992, Journal of the Formosan Medical Association = Taiwan yi zhi.

[15]  R. Portenoy,et al.  Leptomeningeal metastases: Comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias , 1990, Journal of Neuro-Oncology.

[16]  G. Press,et al.  Leptomeningeal metastasis , 1990, Neurology.

[17]  G. Krol,et al.  MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. , 1989, AJNR. American journal of neuroradiology.

[18]  A. Twijnstra,et al.  Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[19]  A. Hart,et al.  Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma , 1983, Neurology.

[20]  J. Hainsworth,et al.  Neoplastic meningitis. , 1983, Journal of the Tennessee Medical Association.

[21]  J. Posner,et al.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients , 1982, Cancer.

[22]  M. Fleisher,et al.  Cerebrospinal fluid biochemical markers of central nervous system metastases , 1980, Annals of neurology.

[23]  N. Chernik,et al.  Malignant cells in cerebrospinal fluid (CSF) , 1979, Neurology.

[24]  J. Reuler,et al.  Leptomeningeal carcinomatosis with normal CSF features. , 1979, Archives of internal medicine.

[25]  Takeshi Kondoh,et al.  Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status. , 2011, Internal medicine.

[26]  A. Leon-Justel,et al.  CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. , 2011, Clinical laboratory.

[27]  Q. Shi,et al.  Optimal cut-off values for tumor markers in cerebrospinal fluid with ROC curve analysis. , 2011, Frontiers in bioscience.

[28]  A. Silvani,et al.  Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers , 2009, Clinical chemistry and laboratory medicine.

[29]  J. Raizer,et al.  Leptomeningeal metastases from solid tumors (meningeal carcinomatosis). , 2005, Cancer treatment and research.

[30]  N. Tsavaris,et al.  Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer , 2005, Medical oncology.

[31]  N. Pavlidis.  The diagnostic and therapeutic management of leptomeningeal carcinomatosis. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  P. Parizel,et al.  Neuroradiologic findings in leptomeningeal carcinomatosis: the value interest of gadolinium-enhanced MRI , 2004, Neuroradiology.